RNA VACCINE PLATFORM
AAHI invented a novel RNA vaccine platform using self-amplifying RNA (saRNA) and a unique RNA delivery vehicle called a nanostructured lipid carrier (NLC).
Innovating RNA vaccine technology to provide flexible and cost-efficient health solutions
ABOUT OUR RNA VACCINE PLATFORM
A Simple, Stable Solution
saRNA that amplifies antigen production in a human cell, is bound to the exterior of the NLC through electrostatic bonding for efficient delivery.
The NLC contains oil at its core with adjuvanting characteristics to boost the immune response to the target disease.
Scalable Manufacturing and Stockpiling
The biggest bottleneck in the commercial production of current RNA vaccine technology is the Lipid Nanoparticle (LNP) manufacturing process in which the RNA is encapsulated inside the LNP formulation. AAHI's RNA platform technology eliminates this step.
AAHI's NLC Vaccine Technology
Current LNP Vaccine Technology
ALTERNATIVE ROUTES OF ADMINISTRATION
Preventing Transmission of Disease
Through alternative administration such as nasal spray and dry powder, AAHI's goal for its RNA vaccine platform technology is to prevent early infection and transmission of disease by enhancing mucosal immunity.
AAHI's RNA vaccine platform technology has demonstrated promising results in preclinical studies evaluating the AAHI-SC2 COVID-19 RNA vaccine candidate administered up the nose.
Novel RNA Solutions
Our team provides innovative RNA solutions to enhance vaccine candidates with next generation features and functionality:
Our team performs: